Gsk Share Discussion Threads

[romeike] 06/7/2017 14:56

A decent extract though I don't agree with "There are diminishing returns in HIV". Where left untreated, caught late or problems with treatment or complications with other issues this virus is as deadly as it ever was, and there's always the threat of new variants appearing that are harder to treat. Unfortunately HIV is far from being tamed and the perception change about HIV is a double edged sword with complacency rising and infection rates stubborn even in the education-rich West.

The fact is when it comes to treating HIV, tackling side effects and compliance ViiV beats out both Gilead and Merck by a long way. Hype around Gilead's latest compound isn't based on large enough studies to show it is better tolerated, in fact I suspect it is not as well tolerated then GSK's three compound regimen and it requires three not two drugs for the regimen, whereas GSK are now racing toward a two drug regimen. Gilead are behind the curve and struggling for resources. Merck isn't even worthy of comparison.

[alphorn] 06/7/2017 14:06

Another key issue is that IP protection looks as though it has 9 years to run.

[romeike] 06/7/2017 13:52

I was being flippant. Their late stage asset is no threat to GSK, their early stage asset is nowhere near developed enough to warrant the suggested impact on ViiV. The analyst is simply exploiting concerns around the technical wobble for ViiV in the last set of results to slam the shares in my view. Fact is ViiV will be back on track in the upcoming results and GSK recovery will be back on track.

[essentialinvestor] 06/7/2017 13:08

Merck have two main HIV assets, one in late Phase 111 testing,
their more interesting prolonged effect compound is only Phase 1.

[ny boy] 05/7/2017 22:36

He's got his gang that wanted to buy in at 1600 not 1700, nothing more than that.

[romeike] 05/7/2017 22:21

How do these idiot analysts keep their jobs? Andrew Baum should quit for this trash analyst report.

[philanderer] 05/7/2017 20:29

Market report: Bearish broker note weighs on GSK

The threat of slowing demand in GlaxoSmithKline’s flagship HIV drug business prompted investors to dump the FTSE 100 stock, sending shares to an eight-week low in intraday trade.

US investment bank Citigroup dealt a blow to the blue chip stock when it downgraded its rating to “neutral” from “buy” and cut its earnings forecast by up to 9pc, as it warned the “HIV market boom years may be over”.

Analyst Andrew Baum also cautioned that the repeal of the Affordable Care Act, or Obamacare, could shrink the US HIV market by increasing the number of uninsured patients and negatively impact prices.

He also argued that rival Merck’s development-stage HIV drug had the “potential to dominate” the market, while Gilead’s single pill treatment could also take market share.

The cautious tone rattled investors, prompting to shares to fall to an intraday low of £15.99, before closing down 3p at £16.26.

[ny boy] 05/7/2017 19:54

Investors largely ignoring recent broker downgrades, judging by the price action today.

[ianood] 05/7/2017 15:56

And that's supposed to be news! Looks like DM is looking for an excuse for recent fall and fell on that rather than the Citibank downgrade to neutral

[ny boy] 05/7/2017 12:19

Some nibbles have come in, not sure if it's the bottom of this cycle but it seemed a reasonable entry level, happy to collect the divis until an overseas predator pounces whilst GSK is cheaply valued!

[ny boy] 05/7/2017 09:43

Ex divi 10 August 2017 pay day 12 October 2017

Next Thursday 13 July pay day for the previous quarter.

[ny boy] 05/7/2017 09:41

Bought £18k for the ISA @ 1600p

[toffeeman] 05/7/2017 09:14

NYB - I know - I hold stock long from 1400 I shorted at resistance for a special dividend :)

[essentialinvestor] 05/7/2017 09:11

Q2 on the 26th.

[ny boy] 05/7/2017 09:10

😂

Close to 5% divi

[tradermichael] 05/7/2017 08:46

toffeeman - excellent move .... ;0)

[ny boy] 05/7/2017 08:25

Good call toffeeman

Chart technicals show 1590p or 1550p as the next support levels.

I would be a buyer around these levels but would be suprised if the market offered me the latter.

[toffeeman] 05/7/2017 08:07

Closed my short for 100 points net - don't want to be greedy :)

[alphorn] 05/7/2017 08:04

GlaxoSmithKline plc (LON:GSK) was downgraded by stock analysts at Citigroup Inc. to a “neutral”; rating in a note issued to investors on Wednesday. They currently have a GBX 1,700 ($22.02) price target on the stock. Citigroup Inc.’s price target would indicate a potential upside of 4.39% from the company’s previous close.

I see that Novartis was also downgraded this morning by Credit Suisse.

[alphorn] 05/7/2017 08:00

Any readers of the GSK pension plans? Appears an amazing investment perfomance last year; must be coming from overseas holdings.

[garycook] 05/7/2017 03:34

NY Boy,ffs stop making prediction,s.You were so wrong with your 285p with PFC.Now you are trying to prove you are an expert on GSK.Your pathetic.Who the hell are you to give predictions anyway.Go forth and multiply !!!

[alphorn] 04/7/2017 11:19

Not sure who the red ticker is - someone who does not know the industry.